New Articles

Rising Prevalence Of Life-Threatening Diseases To Promote Genetic Analysis Market Demand


Rising Prevalence Of Life-Threatening Diseases To Promote Genetic Analysis Market Demand

The genetic analysis market is set to register substantial gains, driven by medical advancements, an increased health-conscious customer base, and the rising prevalence of life-threatening diseases. 

To that end, increasing cognizance toward health has raised the need for the early detection of diseases. In fact, the rising cases of inherited disease-related deaths have shifted the focus of the healthcare industry to genetic analysis.  

Genetic analysis encompasses studying the DNA and RNA patterns for the detection of an ailment. Healthcare industries are rigorously investing in the latest technologies to simplify genetic analysis. 

As per the latest report by Global Market Insights Inc., the genetic analysis market is set to register over $13 billion in revenue by 2030. 

Advanced next-generation sequencing system (NGS) to facilitate precision medicine

The demand for precision medication, which entails metered doses of ingredients as per a patient’s current health, is currently on the rise given the inefficacy put forth by mass-manufactured medications. In this regard, healthcare units are leveraging genome sequencing to identify the patient history for personalizing the medicine. 

The need for rapid testing of huge DNA and RNA samples has compelled geneticists to opt for modernized NGS modules for streamlining precision medicine preparation. Moreover, advanced NGS software like Mapping and Assembly with Quality (MAQ) has come to the forefront for effectively mapping out short reads to reference genomes. 

Europe to emerge as a regional hotspot in genetic analysis industry

The Europe genetic analysis market is expected to witness substantial growth over 2022-2030, owing to the rising prevalence of genetic diseases in the region. As per European Commission, up to 36 million people in the European Union have a rare disease and 80% of them are inherited. In this regard, the region is emphasizing the generation of genomic data to detect infectious and rare diseases for improved diagnosis and disease prevention. 

Europe has also introduced a 1+ Million Genomes initiative that strives to increase genomic health data across Europe for personalized treatment. Besides this, the region is heftily investing to bring advanced technologies in genome sequencing to expand genetic analysis. 

Citing an instance, in December 2021, Hoffmann-La Roche AG, a Swiss multinational healthcare company launched AVENIO Edge System to upgrade genome sequencing. It facilitates real-time tracking of samples and is a cost-effective solution for routine tasks of sequencing laboratories. The solution also helps advance precision medications and increase the accuracy of sequencing by reducing human errors.

Rising prevalence of cardiovascular diseases to foster the market expansion

As per WHO, cardiovascular diseases (CVDs) lead to approximately 17.9 million fatalities annually, being one of the prominent causes of mortality. In the U.S. alone, nearly 697,000 people die from heart disease every year. Such figures have popularized the usage of next-generation sequencing for the detection of complex and inherited CVDs. 

Final thoughts 

It can be inferred that advanced technologies for increasing the accuracy of genetic analysis are set to bolster market expansion. In addition, the prevalence of life-threatening disorders like cancer, CVDs, and infectious diseases and the associated mortality rates is further contributing to the penetration of genetic analysis in many healthcare units. 

Furthermore, government-funded initiatives in healthcare coupled with enhanced genetic testing methods are likely to bring product innovations to the genetic analysis market.


genetic testing

Global Genetic Testing Market to Hit $25 Billion by 2025

Genetic Testing Market is expected to exceed USD 25 billion by 2025. Growing incidences of genetic diseases coupled with the rising availability of advanced genetic tests will augment the industry growth.

Increasing awareness regarding the availability of genetic tests should escalate the genetic testing market growth throughout the forecast years. Industry players implement several promotional activities that raise awareness amongst the people. Moreover, due to increasing internet penetration in developing economies, individuals are becoming aware of the benefits of early diagnosis of genetic diseases. Above mentioned factors should surge the industry growth. However, the high cost of genetic testing may affect industry growth to some extent.

The unprecedented growth pace of the genetic testing market is rather evident from 23andMe’s recent launch of a grant program as a part of its Genotyping services for the research platform. A significant market contributor globally, through this invention, aims at promoting research studies with the intent to increase the revenue shares in the upcoming years. This trend itself bears testimony to the fact that the chief market players are opting for strategic moves to strengthen their position in the global genetic testing market share.

A business vertical of high repute, thriving extensively on personalized medicines, genetic testing market as of today stands as one of the outpaced, profitable industry spheres there is. Endorsed by the availability of technologically sound gene diagnosing kits and elevating cognizance regarding the use of personalized medicines, the commercialization potential of the genetic testing industry has surged immensely in the past few years.

Speaking of the test type spectrum, the carrier testing segment has stood tall during the past few years and is likely to develop at an appreciable pace during 2019-2025. For the records, the carrier testing segment accounted for USD 460 million in 2018. These tests find large scale use among couples to determine the chances of having a child with genetic disorders.

Also, they focus on detecting the probability of a healthy person carrying mutated genes. These factors have prompted healthcare professionals to recommend required treatments for the individuals comprising mutated genes thereby adding an impetus to genetic testing market trends.

North America’s genetic testing market will foresee over 10% growth throughout the forecast years. Increasing prevalence of genetic diseases will prove beneficial for regional growth. Cystic fibrosis, sickle cell anemia, thalassemia, and other genetic disorders affect millions of individuals in the U.S. annually that should spur the demand for upgraded genetic tests. Moreover, favorable regulatory scenario for genetic tests will further positively influence regional growth.

Companies are undertaking several initiatives to add innovations in the genetic testing market. Additionally, industry players such as 23andMe, BGI, BioMerieux, Cepheid, Counsyl and others have implemented several strategic initiatives such as mergers, acquisitions and product launches for gaining competitive advantage. For instance, in October 2016, 23andMe announced the launch of a grant program as part of its Genotyping Services for Research platform. The program is aimed at promoting research studies and obtaining proposals in which 23andMe experience is likely to garner more customers. This strategy will enhance 23andMe’s business grow